JOURNAL ONKOLOGIE – STUDIE
NIFE
Thomas J. Ettrich, Dr.
Principal Investigator
Klinik für Innere Medizin I, Universitätsklinikum Ulm
Helge Schroeder
Kontakt:
E-Mail: Helge.Schroeder@aio-studien-ggmbh.de» Kontaktdaten anzeigen
Thomas J. Ettrich, Dr.
Kontakt:
E-Mail: thomas.ettrich@uniklinik-ulm.de» Kontaktdaten anzeigen
Studienlocations
Leberkrebszentrum Universitätsklinikum Ulm
Albert-Einstein-Allee 23
89081 Ulm
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:
Thomas J. Ettrich, Dr.
E-Mail: thomas.ettrich@uniklinik-ulm.de» Ansprechpartner anzeigen
The primary objective is to determine whether a combination of 5-FU and nal-IRI prolongs progression-free survival in patients with locally advanced or metastatic adenocarcinoma of the biliary tract
1. Written informed consent incl. participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
2. Age ≥ 18 years at time of study entry
3. Histologically confirmed, non-resectable, locally advanced or metastatic adenocarcinoma of the intrahepatic or extrahepatic biliary tract
4. Protocol-specific staging guidelines have to be observed and non-resectability has to be confirmed by local tumor board
5. Measurable or assessable disease according to RECIST 1.1
6. ECOG performance status 0-1
7. Life expectancy of more than 3 months
8. If applicable, adequately treated biliary tract obstruction before study entry with total bilirubin concentration ≤ 2 x ULN
9. Adequate blood count, liver-enzymes, and renal function:
- White blood cell count ≥ 3.5 x 10^6/mL
- Platelet count ≥ 100 x 10^9/L (>100,000 per mm3)
- AST (SGOT)/ALT (SGPT) ≤ 5 x institutional upper limit of normal
- Serum Creatinine ≤ 1.5 x ULN and a calculated glomerular filtration rate ≥ 30 mL per minute
10. Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and PTT < 1.5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of randomization
11. No prior palliative chemotherapy for biliary tract cancer
12. No adjuvant treatment within 6 months prior to study entry
13. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
Exclusion Criteria:
1. Active uncontrolled infection, chronic infectious diseases, immune deficiency syndromes
2. Premalignant hematologic disorders, e.g. myelodysplastic syndrome
3. Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 6 months before enrollment
4. Prior (>5 years) or concurrent malignancy (other than biliary-tract cancer) which either progresses or requires active treatment. Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial bladder tumor [Ta, Tis and T1].
5. Pre-existing lung disease
6. History or clinical evidence of CNS metastases
Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria:
1. are asymptomatic and
2. have no requirement for steroids 6 weeks prior to start of study treatment. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases
7. History of hypersensitivity to any of the study drugs or any of the constituents of the products
8. Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy
9. Severe non-healing wounds, ulcers or bone fractions
10. Evidence of bleeding diathesis or coagulopathy
11. Major surgical procedures, except open biopsy, nor significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study except for surgery of central intravenous line placement for chemotherapy administration.
12. Medication that is known to interfere with any of the agents applied in the trial.
13. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). [Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessary (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (serum β-HCG) at Screening.
14. Known Gilbert-Meulengracht syndrome
15. Known chronic hypoacusis, tinnitus or vertigo
16. Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
17. Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lifes of previously used trial medication, whichever is of longer duration.
18. Previous enrollment or randomization in the present study (does not include screening failure).
19. Any other chemotherapy at study start
20. Involvement in the planning and/or conduct of the study
21. Patient who might be dependent on the sponsor, site or the investigator
22. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities.
23. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts.
1. Progression-free survival [PFS] (Time Frame - approx. 25 months)
Secondary outcome:
1. Overall progression free survival according to RECIST 1.1 (Time Frame - approx. 54 months):
Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
2. 3-years overall survival (Time Frame - approx. 36 months):
3-years overall survival
3. Disease control rate according to RECIST 1.1 (Time Frame - approx. 54 months)
4. Objective tumor response rate (ORR) according to RECIST 1.1 (Time Frame - approx. 54 months):
Proportion of patients with an objective response according to RECIST 1.1
5. Toxicity/Safety according to CTC-AE-criteria (Time Frame - approx. 54 months)
6. Health related quality of life (Time Frame - approx. 54 months):
EORTC QLQ-BIL21
7. Health related quality of life (Time Frame - approx. 54 months):
EORTC QLQ-C30
8. Health related quality of life (Time Frame - approx. 54 months):
Hospital Anxiety and Depression Scale (HADS-D)
9. Retrospective correlation of resectability in accordance with a central surgical board compared to local surgical review (Time Frame - approx. 54 months):
Tumor resectability in accordance with a retrospective central surgical board compared to local surgical review
10. Retrospective central radiological review (Time Frame - approx. 54 months)
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
Rekrutierend
NCT-Nummer:
NCT03044587
Studienbeginn:
Januar 2018
Letztes Update:
09.04.2019
Wirkstoff:
Arm NaI-IRI + 5-FU + Leucovorin (Arm A), Arm Cisplatin + Gemcitabine (Arm B)
Indikation (Clinical Trials):
Carcinoma, Adenocarcinoma, Carcinoma, Hepatocellular, Biliary Tract Neoplasms, Carcinoma, Ductal, Bile Duct Neoplasms, Cholangiocarcinoma
Geschlecht:
Alle
Altersgruppe:
Erwachsene (18+)
Phase:
Phase 2
Sponsor:
AIO-Studien-gGmbH
Collaborator:
SERVIER (Shire, Baxalta), Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH,
Studienleiter
Principal Investigator
Klinik für Innere Medizin I, Universitätsklinikum Ulm
Kontakt
Kontakt:
E-Mail: Helge.Schroeder@aio-studien-ggmbh.de» Kontaktdaten anzeigen
Kontakt:
E-Mail: thomas.ettrich@uniklinik-ulm.de» Kontaktdaten anzeigen
Studienlocations
(1 von 1)
Albert-Einstein-Allee 23
89081 Ulm
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:
Thomas J. Ettrich, Dr.
E-Mail: thomas.ettrich@uniklinik-ulm.de» Ansprechpartner anzeigen
Studien-Informationen
Detailed Description:The primary objective is to determine whether a combination of 5-FU and nal-IRI prolongs progression-free survival in patients with locally advanced or metastatic adenocarcinoma of the biliary tract
Ein-/Ausschlusskriterien
Inclusion Criteria:1. Written informed consent incl. participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
2. Age ≥ 18 years at time of study entry
3. Histologically confirmed, non-resectable, locally advanced or metastatic adenocarcinoma of the intrahepatic or extrahepatic biliary tract
4. Protocol-specific staging guidelines have to be observed and non-resectability has to be confirmed by local tumor board
5. Measurable or assessable disease according to RECIST 1.1
6. ECOG performance status 0-1
7. Life expectancy of more than 3 months
8. If applicable, adequately treated biliary tract obstruction before study entry with total bilirubin concentration ≤ 2 x ULN
9. Adequate blood count, liver-enzymes, and renal function:
- White blood cell count ≥ 3.5 x 10^6/mL
- Platelet count ≥ 100 x 10^9/L (>100,000 per mm3)
- AST (SGOT)/ALT (SGPT) ≤ 5 x institutional upper limit of normal
- Serum Creatinine ≤ 1.5 x ULN and a calculated glomerular filtration rate ≥ 30 mL per minute
10. Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and PTT < 1.5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of randomization
11. No prior palliative chemotherapy for biliary tract cancer
12. No adjuvant treatment within 6 months prior to study entry
13. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
Exclusion Criteria:
1. Active uncontrolled infection, chronic infectious diseases, immune deficiency syndromes
2. Premalignant hematologic disorders, e.g. myelodysplastic syndrome
3. Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 6 months before enrollment
4. Prior (>5 years) or concurrent malignancy (other than biliary-tract cancer) which either progresses or requires active treatment. Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial bladder tumor [Ta, Tis and T1].
5. Pre-existing lung disease
6. History or clinical evidence of CNS metastases
Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria:
1. are asymptomatic and
2. have no requirement for steroids 6 weeks prior to start of study treatment. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases
7. History of hypersensitivity to any of the study drugs or any of the constituents of the products
8. Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy
9. Severe non-healing wounds, ulcers or bone fractions
10. Evidence of bleeding diathesis or coagulopathy
11. Major surgical procedures, except open biopsy, nor significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study except for surgery of central intravenous line placement for chemotherapy administration.
12. Medication that is known to interfere with any of the agents applied in the trial.
13. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). [Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessary (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (serum β-HCG) at Screening.
14. Known Gilbert-Meulengracht syndrome
15. Known chronic hypoacusis, tinnitus or vertigo
16. Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
17. Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lifes of previously used trial medication, whichever is of longer duration.
18. Previous enrollment or randomization in the present study (does not include screening failure).
19. Any other chemotherapy at study start
20. Involvement in the planning and/or conduct of the study
21. Patient who might be dependent on the sponsor, site or the investigator
22. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities.
23. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts.
Studien-Rationale
Primary outcome:1. Progression-free survival [PFS] (Time Frame - approx. 25 months)
Secondary outcome:
1. Overall progression free survival according to RECIST 1.1 (Time Frame - approx. 54 months):
Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
2. 3-years overall survival (Time Frame - approx. 36 months):
3-years overall survival
3. Disease control rate according to RECIST 1.1 (Time Frame - approx. 54 months)
4. Objective tumor response rate (ORR) according to RECIST 1.1 (Time Frame - approx. 54 months):
Proportion of patients with an objective response according to RECIST 1.1
5. Toxicity/Safety according to CTC-AE-criteria (Time Frame - approx. 54 months)
6. Health related quality of life (Time Frame - approx. 54 months):
EORTC QLQ-BIL21
7. Health related quality of life (Time Frame - approx. 54 months):
EORTC QLQ-C30
8. Health related quality of life (Time Frame - approx. 54 months):
Hospital Anxiety and Depression Scale (HADS-D)
9. Retrospective correlation of resectability in accordance with a central surgical board compared to local surgical review (Time Frame - approx. 54 months):
Tumor resectability in accordance with a retrospective central surgical board compared to local surgical review
10. Retrospective central radiological review (Time Frame - approx. 54 months)
Studien-Arme
- Experimental: Arm NaI-IRI + 5-FU + Leucovorin (Arm A)
Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w - Other: Arm Cisplatin + Gemcitabine (Arm B, standard of care)
Cisplatin, Gemcitabine Cycle q3w
Geprüfte Regime
- Arm NaI-IRI + 5-FU + Leucovorin (Arm A):
Nal-IRI (80 mg/m2 as a 1.5 hour infusion), 5-FU (2400 mg/m2 as 46 hour infusion) and Leucovorin (400 mg/m2 as 0.5 hour infusion) Cycle q2w - Arm Cisplatin + Gemcitabine (Arm B):
Cisplatin (25 mg/m2 as 1 hour infusion on D1, D8) and Gemcitabine (1000 mg/m2 as 0.5 hour infusion on D1, D8) Cycle q3w
Quelle: ClinicalTrials.gov
Das könnte Sie auch interessieren
